The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
Pure Cycle Corp
PCYO · NASDAQ · USD · Market cap $258M · 44 employees
Pure Cycle Corporation provides water and wastewater services in the United States.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price10.82 USD at the 13 Nov 2026 close
- Fair value5.41. Our model only; no analyst estimate to cross-check.
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkdown, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.26)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available, base estimate $5.41 (screen dated 2026-11-13).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.26, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Pure Cycle Corp holds its Markdown at $10.82. The statistical read favours the buyers, held for 1 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the buyers, held for 1 days |
| Price at the screen | $10.82 |
| Valuation | 18.25 trailing · 123.67 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.23 |
Five Screens, Shown in Full
Does not pass. Revenue purity
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 4.19% | Below 33% | Interest-bearing debt is just 4.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 14.33% | Below 49% | Money owed to the company is 14.3% of assets, under the 49% limit. | Pass |
| Revenue purity | 12.54% | Below 5% | 12.5% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Pure Cycle clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 13% of its income right now is non-operating interest income, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PCYO's ethical verdict changes
Today PCYO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our model only; no analyst estimate to cross-check.
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $5.41 fair value estimate, none competitive moat, 60.00% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 100.0% above the base estimate.
Where our models see it going: fair-value estimate $5.41, range not available, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 123.7x forward earnings, the price already runs ahead of the business. It trades 100% above our $5.41 fair value, so you would be buying at a premium, not a discount. The none moat is real, but quality alone does not make an expensive price cheap.
| Forward P/E | 123.7xexpensive even after accounting for its growth |
| Trailing P/E | 18.3xreasonably valued |
| EPS, trailing | 0.61 |
| EPS, forward | 0.09 |
| Revenue growth | +60.0%growing very fast |
| Profit margin | 43.7%highly profitable on every dollar of sales |
| Return on equity | 10.2%a modest return on shareholder capital |
| FCF yield | -0.94% |
| Debt to equity | 0.09minimal debt: a conservative balance sheet |
| Current ratio | 1.53healthy short-term liquidity |
| Beta | 1.23moves a little more than the market |
| Short interest, float | 0.02% |
| 52-week range | 9.65 - 12.44 |
| Moat | NONE |
| Market cap | $258M |
| Employees | 44 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePCYO trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $11.56 | -8.9% | · | $911 | -8.9% |
| 2 months | $11.23 | -6.2% | · | $938 | -6.2% |
| 3 months | $10.08 | +4.5% | · | $1,045 | +4.5% |
| 6 months | $11.80 | -10.8% | · | $892 | -10.8% |
| 1 year | $10.73 | -1.9% | · | $981 | -1.9% |
| 2 years | $9.15 | +15.1% | · | $1,151 | +15.1% |
| 3 years | $10.21 | +3.1% | · | $1,031 | +3.1% |
| 5 years | $13.87 | -24.1% | · | $759 | -24.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PCYO does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.